Laurus Labs Limited (LAURUSLABS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Laurus Labs Limited (LAURUSLABS) has a cash flow conversion efficiency ratio of 0.222x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs10.93 Billion ≈ $118.22 Million USD) by net assets (Rs49.34 Billion ≈ $533.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Laurus Labs Limited - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Laurus Labs Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Laurus Labs Limited total liabilities for a breakdown of total debt and financial obligations.
Laurus Labs Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Laurus Labs Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MSA Safety
NYSE:MSA
|
0.090x |
|
GXO Logistics Inc
NYSE:GXO
|
-0.623x |
|
Celanese Corporation
NYSE:CE
|
0.102x |
|
Tencent Music Entertainment Group
NYSE:TME
|
0.043x |
|
Anhui Gujing Distillery Co Ltd
SHE:000596
|
-0.057x |
|
Anji Microelectronics Tech Co Ltd
SHG:688019
|
0.006x |
|
Triple Flag Precious Metals Corp
TO:TFPM
|
0.044x |
|
Leo Group Co Ltd
SHE:002131
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Laurus Labs Limited (2013–2025)
The table below shows the annual cash flow conversion efficiency of Laurus Labs Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Laurus Labs Limited worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs46.03 Billion ≈ $497.75 Million |
Rs6.02 Billion ≈ $65.07 Million |
0.131x | -19.18% |
| 2024-03-31 | Rs41.16 Billion ≈ $445.08 Million |
Rs6.66 Billion ≈ $71.99 Million |
0.162x | -34.11% |
| 2023-03-31 | Rs40.49 Billion ≈ $437.85 Million |
Rs9.94 Billion ≈ $107.49 Million |
0.245x | -9.49% |
| 2022-03-31 | Rs33.59 Billion ≈ $363.27 Million |
Rs9.11 Billion ≈ $98.53 Million |
0.271x | -3.76% |
| 2021-03-31 | Rs26.01 Billion ≈ $281.26 Million |
Rs7.33 Billion ≈ $79.27 Million |
0.282x | +43.58% |
| 2020-03-31 | Rs17.70 Billion ≈ $191.39 Million |
Rs3.47 Billion ≈ $37.57 Million |
0.196x | +2.77% |
| 2019-03-31 | Rs15.58 Billion ≈ $168.54 Million |
Rs2.98 Billion ≈ $32.19 Million |
0.191x | -17.32% |
| 2018-03-31 | Rs14.83 Billion ≈ $160.34 Million |
Rs3.42 Billion ≈ $37.04 Million |
0.231x | -7.42% |
| 2017-03-31 | Rs13.30 Billion ≈ $143.88 Million |
Rs3.32 Billion ≈ $35.90 Million |
0.250x | +9.96% |
| 2016-03-31 | Rs8.52 Billion ≈ $92.12 Million |
Rs1.93 Billion ≈ $20.90 Million |
0.227x | +352.81% |
| 2015-03-31 | Rs7.21 Billion ≈ $77.96 Million |
Rs-647.06 Million ≈ $-7.00 Million |
-0.090x | -126.54% |
| 2014-03-31 | Rs3.58 Billion ≈ $38.76 Million |
Rs1.21 Billion ≈ $13.11 Million |
0.338x | -0.57% |
| 2013-03-31 | Rs2.59 Billion ≈ $28.04 Million |
Rs882.08 Million ≈ $9.54 Million |
0.340x | -- |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more